Literature DB >> 12807338

Pharmacological profile of extracts of Pelargonium sidoides and their constituents.

Herbert Kolodziej1, Oliver Kayser, Oliver A Radtke, Albrecht F Kiderlen, Egon Koch.   

Abstract

In areas of southern Africa, aqueous extracts from the roots of Pelargonium sidoides are employed to cure various disorders. Nowadays, a modern formulation (EPs 7630), elaborated from the traditional herbal medicine, is successfully used for the treatment of respiratory tract diseases. We previously observed that root extracts of P. sidoides and their representative constituents exhibit moderate antibacterial and significant immunomodulatory capabilities. The present study was performed to further assess the efficacy and mode of action for these pharmacological activities. The results indicate that P. sidoides extracts may well possess antimycobacterial activity as claimed in traditional uses. Furthermore, significant antibacterial properties against multi-resistant Staphylococcus aureus strains as well as TNF-inducing potencies and prominent interferon-like activities in supernatants of sample-activated bone marrow-derived macrophages were observed using several functional assays. In addition, EPs 7630 stimulated the synthesis of IFN-beta in MG 63 cells as demonstrated by a specific enzyme immunoassay. For gallic acid, a characteristic constituent, evidence for the expression of iNOS and TNF-alpha transcripts in stimulated RAW 264.7 cells and, hence, activation at the transcriptional level was revealed by RT-PCR. The present results, when taken together with the recently reported pharmacological activities, provide for a rationale basis of the utilization of EPs 7630 in the treatment of respiratory tract infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12807338     DOI: 10.1078/1433-187x-00307

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  15 in total

1.  A Pragmatic Approach to Immunity & Respiratory Viral Infections.

Authors:  Todd A Born
Journal:  Integr Med (Encinitas)       Date:  2020-10

2.  Exploring the anti-proliferative activity of Pelargonium sidoides DC with in silico target identification and network pharmacology.

Authors:  A S P Pereira; M J Bester; Z Apostolides
Journal:  Mol Divers       Date:  2017-09-18       Impact factor: 2.943

Review 3.  COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

Authors:  Dâmaris Silveira; Jose Maria Prieto-Garcia; Fabio Boylan; Omar Estrada; Yris Maria Fonseca-Bazzo; Claudia Masrouah Jamal; Pérola Oliveira Magalhães; Edson Oliveira Pereira; Michal Tomczyk; Michael Heinrich
Journal:  Front Pharmacol       Date:  2020-09-23       Impact factor: 5.810

Review 4.  [Pelargonium sidoides-extract (EPs 7630): registration confirms efficacy and safety].

Authors:  Andreas Conrad; Herbert Kolodziej; Volker Schulz
Journal:  Wien Med Wochenschr       Date:  2007

5.  Anti-inflammatory Effects of Pelargonium endlicherianum Fenzl. Extracts in Lipopolysaccharide-stimulated Macrophages.

Authors:  Ahmet Cumaoğlu; Gökçe Şeker Karatoprak; Mükerrem Betül Yerer; Müberra Koşar
Journal:  Turk J Pharm Sci       Date:  2018-04-02

Review 6.  Antimicrobial, Antiviral and Immunomodulatory Activity Studies of Pelargonium sidoides (EPs® 7630) in the Context of Health Promotion.

Authors:  Herbert Kolodziej
Journal:  Pharmaceuticals (Basel)       Date:  2011-10-10

Review 7.  Pelargonium sidoides extract EPs 7630: a review of its clinical efficacy and safety for treating acute respiratory tract infections in children.

Authors:  Domenico Careddu; Andrea Pettenazzo
Journal:  Int J Gen Med       Date:  2018-03-08

8.  Faster recovery and reduced paracetamol use - a meta-analysis of EPs 7630 in children with acute respiratory tract infections.

Authors:  Georg Seifert; Juliette Brandes-Schramm; Andrea Zimmermann; Walter Lehmacher; Wolfgang Kamin
Journal:  BMC Pediatr       Date:  2019-04-23       Impact factor: 2.125

9.  The Pelargonium sidoides Extract EPs 7630 Drives the Innate Immune Defense by Activating Selected MAP Kinase Pathways in Human Monocytes.

Authors:  Katrin Witte; Egon Koch; Hans-Dieter Volk; Kerstin Wolk; Robert Sabat
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

Review 10.  Complementary and integrative treatments: rhinosinusitis.

Authors:  Malcolm B Taw; Chau T Nguyen; Marilene B Wang
Journal:  Otolaryngol Clin North Am       Date:  2013-04-28       Impact factor: 3.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.